Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Study hints of rituximab MS benefit
Morphological differentiation of oligodendrocytes requires activation of Fyn tyrosine kinase.
Colestipol May Quickly Eliminate Teriflunomide
Binding of recombinant T cell receptor ligands (RTL) to antigen presenting cells prevents upregulation of CD11b and inhibits T cell activation and transfer of experimental autoimmune encephalomyelitis.
Lights and shadows of cyclophosphamide in the treatment of multiple sclerosis.
Human endogenous retroviruses and multiple sclerosis: innocent bystanders or disease determinants?
Human herpesvirus 6 and effectiveness of interferon β1b in multiple sclerosis patients.
Reactive astrocytes as therapeutic targets for CNS disorders.
Ofatumumab
Daclizumab for relapsing remitting multiple sclerosis.
Pharmacokinetic properties and metabolism of idebenone.
Treatment of primary Sjögren syndrome with rituximab: a randomized trial.
Self-reactive CD4(+) T cells activated during viral-induced demyelination do not prevent clinical recovery.
Quantitative assays for anti-aquaporin-4 antibody with subclass analysis in neuromyelitis optica.
CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS.
Cutaneous adverse events in multiple sclerosis patients treated with daclizumab.
Estimating Time to Disease Progression Comparing Transition Models and Survival Methods-An Analysis of Multiple Sclerosis Data.
Long-Term Safety and Efficacy Study of BIIB017 (PEGylated Interferon Beta-1a) (ATTAIN)
Exercise and disease progression in multiple sclerosis: can exercise slow down the progression of multiple sclerosis?
Tumefactive Multiple Sclerosis presenting as Acute Ischemic Stroke.
Differential roles of microglia and monocytes in the inflamed central nervous system.
MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study.
Multiple sclerosis: an immune or neurodegenerative disorder?
Alerting Network Dysfunction in Early Multiple Sclerosis.
Sanofi MS drug nears green light after pass-the-parcel marathon

Pages